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PAspirin Resistance
verestimation of Platelet Aspirin
esistance Detection by Thrombelastograph
latelet Mapping and Validation by Conventional
ggregometry Using Arachidonic Acid Stimulation
daya S. Tantry, PHD, Kevin P. Bliden, BS, Paul A. Gurbel, MD, FACC
altimore, Maryland
OBJECTIVES This study sought to determine the prevalence of platelet aspirin resistance using methods
that directly indicate the degree of platelet cyclooxygenase inhibition.
BACKGROUND Aspirin resistance in platelets may be overestimated by nonspecific laboratory measurements
that do not isolate cyclooxygenase activity.
METHODS Arachidonic acid (AA)-induced light-transmittance platelet aggregation (LTA) and throm-
belastography (TEG) platelet mapping were performed on the blood of healthy subjects (n
6) before and 24 h after receiving 325 mg aspirin, and on 223 patients reporting compliance
with long-term daily aspirin treatment (n 203 undergoing percutaneous intervention [PCI]
and n  20 with a history of stent thrombosis). Aspirin resistance was defined as 20%
aggregation by LTA or 50% aggregation by TEG.
RESULTS In healthy subjects, AA-induced aggregation by LTA was 82  10% before and 2  1% at
24 h after aspirin (p  0.001), and aggregation by TEG was 86  14% before and 5  7%
at 24 h after aspirin (p 0.001). In compliant patients, AA-induced aggregation by LTA was
3  2% before PCI and 3  2% after PCI (p  NS), and aggregation by TEG was 5  9%
before PCI and 6  14% after PCI (p  NS). Seven PCI patients were noncompliant, and
all were aspirin sensitive after in-hospital aspirin treatment. Among 223 patients, only one
patient (0.4%) was resistant to aspirin treatment.
CONCLUSIONS Platelet aspirin resistance assessed by methods that directly indicate inhibition of cyclooxy-
genase is rare in compliant patients with coronary artery disease. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.09046:1705–9) © 2005 by the American College of Cardiology Foundation
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phe occurrence of ischemic events in patients treated with
spirin has been attributed by some investigators to drug
esistance (1–5). Aspirin “resistance” has been assessed by
arious laboratory methods that assess platelet function after
timulation by agonists such as cationic propyl gallate,
rachidonic acid (AA), adenosine diphosphate (ADP), epi-
ephrine, and collagen. Initially, using light-transmittance
ggregometry (LTA) with both AA and ADP as agonists,
See page 1710
um et al. (3) reported a 5% prevalence of aspirin resistance
n patients with stable coronary artery disease. With the
ltegra point-of-care Rapid Platelet Function Assay-ASA
Accumetrics Inc., San Diego, California), in which cationic
ropyl gallate is used as an agonist, the prevalence of aspirin
esistance was 19% to 23% (4,5). Using the PFA-100
Dade-Behring Inc., West Sacramento, California) point-
f-service assay, which uses collagen and epinephrine as the
gonists, the prevalence of aspirin resistance was 35% in
ost-myocardial infarction patients (6). The Working
From the Sinai Center for Thrombosis Research, Baltimore, Maryland. This study
as supported by the Sinai Center for Thrombosis Research, Baltimore, Maryland.p
Manuscript received March 21, 2005; revised manuscript received May 13, 2005,
ccepted May 22, 2005.roup on Aspirin Resistance, International Society on
hrombosis and Haemostasis, has written a position state-
ent that summarizes the limitations of the current meth-
ds of assessing aspirin responsiveness (7). Because the
arget of aspirin therapy is inhibition of cyclooxygenase-1
COX-1), methods that directly indicate the activity of this
nzyme would best assess whether aspirin resistance is
resent in a given patient (8). However, there is no
niformity in either the laboratory methodologies to detect
spirin resistance or the criteria to define aspirin resistance.
oreover, numerous methods that are reported to deter-
ine aspirin resistance are strongly affected by pathways of
latelet activation other than COX-1. This fact has been
roposed as an explanation for the high prevalence of
esistance reported in some studies (7–10).
We hypothesized that the prevalence of platelet aspirin
esistance is rare when assessed by methods that directly
easure the inhibition of platelet COX-1 activity by
spirin. COX-1 converts AA into prostaglandin G2/
rostaglandin H2, which then is converted to thrombox-
ne A2 by thromboxane synthase in platelets. Therefore,
e conducted a prospective investigation assessing the
revalence of aspirin resistance using methods that em-
loy AA as the agonist. These studies were conducted in
latelet-rich plasma (PRP) and also whole blood to
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latelet aggregation (11,12).
ETHODS
atients. The study was approved by the Investigational
eview Board of the Sinai Hospital of Baltimore. Two
undred three consecutive patients undergoing coronary
tenting were prospectively studied. Twenty patients with a
istory of stent thrombosis (SAT) were identified by review
f medical records and were contacted for the study. All
atients reported compliance with long-term aspirin ther-
py. All patients undergoing stenting received 325 mg
spirin on the day of the procedure and daily thereafter. All
atients who suffered SAT were on a maintenance dose of
5 mg/day clopidogrel at the time of the blood draw.
eventy percent of the patients who underwent percutane-
us coronary intervention (PCI) were not on a maintenance
ose of clopidogrel before the procedure and received a 300-
r 600-mg clopidogrel loading dose during the procedure
ollowed by a 75-mg/day maintenance dose thereafter.
hirty percent of the PCI patients were on a 75-mg daily
lopidogrel maintenance dose before the procedure and did
ot receive a further loading dose.
ontrol subjects. Six healthy subjects were studied before
nd 24 h after receiving 325 mg aspirin.
lood samples. Blood was collected in a blood collection
ube containing 3.8% trisodium citrate for LTA and con-
aining 40 USP lithium heparin tube (United States Phar-
acopeia, Rockville, Maryland) for thrombelastography
TEG), filled to capacity, and then inverted three to five
imes for gentle mixing. Blood samples were obtained
efore clopidogrel loading and heparin and glycoprotein
GP) IIb/IIIa receptor inhibitor administration (baseline),
nd at 24 h after the procedure in those patients not
eceiving GP IIb/IIIa inhibitors. In patients receiving GP
Ib/IIIa inhibitors, blood samples were evaluated at five to
even days after the procedure. All patients with a history of
Abbreviations and Acronyms
AA  arachidonic acid
ADP  adenosine diphosphate
COX-1  cyclooxygenase-1
GP  glycoprotein
LTA  light-transmittance aggregometry
MAAA  arachidonic acid-induced clot strength
(measurement of aspirin effect)
MAfibrin  activator-induced clot strength
(measurement of fibrin contribution)
MAthrombin  thrombin-induced clot strength (maximum
clot strength)
PCI  percutaneous coronary intervention
PPP  platelet-poor plasma
PRP  platelet-rich plasma
SAT  stent thrombosis
TEG  thrombelastographyubacute thrombosis were confirmed to be on aspirin treat- went at the time of blood drawing. Healthy subjects had
lood drawn immediately before receiving 325 mg aspirin
nd then 24 h later.
latelet function studies. LTA. The blood-citrate mixture
as centrifuged at 120 g for five minutes, and PRP was
ecovered. The blood-citrate mixture was subjected to fur-
her centrifugation at 850 g for five minutes to recover
latelet-poor plasma (PPP). Aggregation was assessed using
Chronolog Lumi-aggregometer (model 490, Chronolog,
averton, Pennsylvania) with the Aggrolink software pack-
ge as previously described (13). We assessed the aggrega-
ion effect of 1 mmol/l and 2 mmol/l AA in the first 40
atients and found no differences between the two AA
oncentrations (data not shown). Therefore, platelets were
timulated with 1 mmol/l AA in the remaining PRP
amples and platelet aggregation was expressed as the
aximal percent change in light transmittance from base-
ine, using PPP as a reference.
AEMOSCOPE THROMBELASTOGRAPH (TEG) PLATELET
APPING ASSAY. The recent U.S. Food and Drug
dministration-approved TEG Platelet Mapping assay
Haemoscope Corporation, Niles, Illinois) relies on the
easurement of clot strength to enable a quantitative
nalysis of platelet function. The assay uses heparin as an
nticoagulant to eliminate thrombin activity in the sample.
eptilase and factor XIIIa (activator F) are used to generate
cross-linked fibrin clot to isolate the fibrin contribution to
he clot strength (14). The contribution of P2Y12 receptor
r COX pathways to the clot formation can be measured by
he addition of an appropriate agonist, ADP or AA.
herefore, AA is added to activator F to measure the degree
f thromboxane A2-induced platelet aggregation.
Blood was analyzed according to the manufacturer’s
nstructions. One milliliter of heparinized blood was trans-
erred to a vial containing kaolin and mixed by inversion.
ive hundred microliters of the activated blood was then
ransferred to a vial containing heparinase and mixed to
eutralize heparin. The neutralized blood (360 l) was
mmediately added to a heparinase-coated cup and assayed
n the TEG analyzer to measure the thrombin-induced clot
trength (MAthrombin). Heparinized blood (340 l) was
dded to a non-coated cup containing reptilase and activator
to generate a whole-blood fibrin cross-linked clot in the
bsence of thrombin generation or platelet stimulation
MAfibrin). A third sample (340 l) of heparinized blood
as added to a non–heparinase-coated cup in the presence
f the activator F and AA (1 mmol/l) to generate whole-
lood cross-linked clot with platelet activation (MAAA).
latelet aggregation in response to AA is calculated using
omputerized software based on the formula: % aggregation
[(MAAA  MAfibrin)/(MAthrombin  MAfibrin)]  100.
efinition of aspirin resistance. In this study we mea-
ured platelet response to aspirin therapy by measuring the
ggregation in both PRP (LTA) and whole blood (TEG)
ith 1 mmol/l AA as the agonist. Because whole-blood
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November 1, 2005:1705–9 Aspirin Resistanceggregation in the TEG assay includes fibrin generation and
he interaction of platelets with fibrin, higher values of
ggregation are expected compared with data obtained from
RP. Therefore, aspirin resistance is defined as the occur-
ence of more than 20% platelet aggregation after stimula-
ion by 1 mmol/l AA as measured by LTA or more than
0% platelet aggregation after stimulation by 1 mmol/l AA
s measured by TEG after aspirin therapy.
tatistical analysis. Comparisons were made within
roups between baseline and post-treatment by t tests, and
 0.05 was considered significant. Based on the normal
istribution of data, the mean value  standard deviation
as used. A standard regression analysis was performed to
orrelate aggregation by conventional LTA with TEG
easurements of aggregation. In the present study, we
ypothesized that by using light transmittance aggregom-
try with 1 mmol/l AA as the agonist, the prevalence of
spirin resistance is 5%. Based on the formula: n  15.4 
 (1  p)/w2, in which n  number of patients required,
 prevalence of aspirin resistance (5%), and w is the
esired width of 95% confidence interval ( 6%), 200
atients were required to complete the study.
ESULTS
ealthy subjects and patients. Healthy subjects were
5  5 years old and had no modifiable cardiovascular risk
able 1. Patient Demographics and Procedural Characteristics
Patients
Undergoing
PCI
(n  203)
Patients
With Stent
Thrombosis
(n  20)
ge (yrs) 63  17 65  11
ace (caucasian) (%) 75 50
ender (male) (%) 60 50
isk factors/past medical history (%)
Smoking 61 45
Family history of coronary artery
disease
53 80
Hypertension 73 75
Hyperlipidemia 75 75
Diabetes 38 60
Prior myocardial infarction 16 60
Prior CABG graft 16 25
Prior PTCA 24 20
aseline medications (%)
Beta-blockers 81 85
ACE inhibitors 69 75
Calcium blockers 19 25
Lipid-lowering agents 71 80
Clopidogrel 30 100
Aspirin 100 100
rocedural variables
Total lesion length, mm 20  12 24  6
Reference vessel diameter, mm 3.1  0.4 2.8  0.3
Number of vessels treated 1.4  0.6 1.3  0.4
CE  angiotensin-converting enzyme; CABG  coronary artery bypass graft;
CI  percutaneous coronary intervention; PTCA  percutaneous transluminal
oronary angioplasty.actors. Among the patients undergoing PCI, all procedures
(
terformed were non-emergent; 36 patients were admitted with
nstable angina, and 11 patients had non–ST-segment eleva-
ion myocardial infarction. The remainder of the patients had
table angina. In the patients with a history of SAT, the mean
ime from the index procedure to SAT was 23 16 days. The
verage time from the occurrence of SAT to blood drawing for
aboratory evaluation was 218  204 days. The patient
emographics and procedural characteristics of patients under-
oing PCI and patients with SAT are shown in Table 1. All
atients undergoing PCI and all patients who suffered SAT
eported taking aspirin 325 mg daily.
re-treatment aggregation. CONTROL SUBJECTS. The
TA and TEG analyses were completed in all patients (n
23) and healthy subjects (n  6). In healthy subjects,
A-induced aggregation by LTA was 82  10% and by
EG was 86  14% before aspirin, and it decreased
ignificantly after aspirin treatment (2  1% by LTA and 5
7% by TEG, respectively [p  0.001]), indicating the
omplete inhibition of COX-1 by a 325-mg aspirin dose
Figs. 1 and 2).
CI PATIENTS. In patients undergoing PCI (n 203), all of
hom claimed compliance with aspirin therapy, pre-PCI
A-induced platelet aggregation by LTA and TEG was
ow (5  14% and 7  17%, respectively). Seven PCI
atients had high aggregation by LTA and TEG and
dmitted non-compliance with aspirin therapy. In these
on-compliant patients, aggregation by LTA was 73 21%
efore PCI and decreased to 2  2% post-PCI after
n-hospital treatment with 325 mg aspirin (p  0.001).
imilarly, aggregation by TEG was 72  27% before PCI
nd 7  13% post-PCI after treatment with 325 mg aspirin
p  0.001). Thus, all patients in the non-compliant group
ere found to be aspirin sensitive.
All patients in the compliant group (n  196) were
spirin sensitive. Pre-PCI and post-PCI aggregation by
TA was 3  2% and 3  2%, respectively (p  NS).
igure 1. Scatter plot showing 1 mmol/l arachidonic acid-induced platelet
ggregation by light-transmittance aggregometry in individual healthy
ubjects (n 6) (before and after aspirin therapy), compliant (n 196) and
on-compliant patients (n  7) undergoing percutaneous interventions
PCIs) (before and after PCI), and patients with a history of stent
hrombosis (SAT).
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Aspirin Resistance November 1, 2005:1705–9ggregation by TEG was 4 9% before PCI and 6 14%
fter PCI (p  NS).
ATIENTS WITH SAT. In patients with SAT (n  20),
A-induced platelet aggregation by LTA was 6 12% and
y TEG was 9  20%. One patient met the definition of
spirin resistance; AA-induced aggregation was 54% by
TA and 85% by TEG in that patient. Therefore, among
23 patients with coronary artery disease evaluated in our
nvestigation, only one patient (0.4%), who also had a
istory of SAT, was resistant to aspirin treatment.
ORRELATION OF AGGREGATION MEASURED BY LTA AND
EG. The PRP aggregation measured by LTA strongly
orrelated with aggregation measured in whole blood by
EG (r  0.85, p  0.001). All of the non-compliant
atients had high aggregation by both TEG and LTA
Figs. 1 and 2).
ISCUSSION
he present study suggests that aspirin resistance is rare in
ompliant patients with coronary artery disease when as-
essed by methods directly dependent on platelet COX-1.
n our study, only one of 223 patients (0.4%) was resistant
o aspirin treatment. The concordant data in whole blood
nd PRP suggest that other cells do not significantly
nfluence ex vivo platelet responsiveness to aspirin.
The antiplatelet effect of aspirin is based on its irreversible
cetylation of cyclooxygenase, specifically the COX-1 isoen-
yme in platelets. The COX-1 enzyme catalyzes the con-
ersion of AA to prostaglandin H2 and subsequent synthesis
f thromboxane A2, a potent platelet agonist. Thus the ideal
aboratory evaluation of the antiplatelet effect of aspirin
hould include the functional response of platelets to AA or
easurement of the levels of thromboxane B2, a stable
etabolite of thromboxane A2.
The earlier studies of Gum et al. (3) used 20%
A-induced platelet aggregation and 70% ADP-induced
ggregation as criteria for defining aspirin resistance. The
igure 2. Scatter plot showing 1 mmol/l arachidonic acid-induced platelet
ggregation by thrombelastography in individual healthy subjects (n  6)
before and after aspirin therapy), compliant (n  196) and non-compliant
atients (n 7) undergoing percutaneous interventions (PCIs) (before and
fter PCI), and patients with a history of stent thrombosis (SAT).oncentration of AA used by Gum et al. (3) was 1.6 mmol/l, ohereas we analyzed AA-induced aggregation at 1.0
mol/l. The differences in the estimate of resistance based
n AA-induced aggregation between the two studies may
e in part caused by the difference in the AA concentration
sed in two studies. However, we compared the effect of 1
mol/l AA and 2 mmol/l AA on platelet aggregation in the
rst 40 patients and found no difference in platelet aggre-
ation. Therefore, on the remaining patients we used 1
mol/l AA. Finally, the patient population studied, the
ose of aspirin used, and also the strict in-hospital compli-
nce measures used in our study may have affected the
esults.
Since the original study by Gum et al. (3), other inves-
igators have used various methods such as the bleeding
ime and cationic propyl gallate-, ADP-, epinephrine-, and
ollagen-induced aggregation to assess aspirin responsive-
ess (1–6). The latter methods affect platelet aggregation by
athways that include but are not specific to COX-1 (7–8).
oreover, the definition of aspirin resistance also varied
epending on the assay. Recently, aspirin resistance has
een reported by using point-of-service assays. The PFA-
00 assay is partially dependent on epinephrine-induced
ggregation and thus does not solely isolate COX activity
6). The Ultegra assay estimated aspirin resistance by using
ationic propyl gallate to indirectly influence AA metabo-
ism (4,5). Thus, stimulation with a known concentration of
A, a direct substrate of the COX-1 enzyme, was not
onducted in the latter studies.
In the present study, we evaluated the platelet response to
spirin in PRP and in whole blood. Moreover, both meth-
ds strongly correlated in measuring AA-induced platelet
ggregation. Finally, we evaluated the efficacy of 325-mg
spirin therapy in patients and healthy subjects. Among the
23 patients enrolled in the study, 3% were found non-
ompliant with aspirin therapy and were therefore pseudo
on-responders. This finding is concordant with previous
eports (15,16). In-hospital treatment of these non-
ompliant patients with 325 mg aspirin showed that they
ere indeed sensitive to aspirin therapy. Only one patient
ho suffered an SAT was found to be resistant to aspirin
herapy as measured by both LTA and TEG. The latter
nding suggests that aspirin non-responsiveness may be a
isk factor for ischemic events after stenting, as has been
eported by other investigators (1–6).
The rare occurrence of aspirin resistance in the present
tudy strongly suggests that the occurrence of aspirin resis-
ance in published reports is overestimated. As can be seen
ith the non-compliant subgroup of patients in our study,
utpatient treatment and lack of compliance are important
onsiderations in determining the prevalence of aspirin
esistance. In addition, use of COX-1–specific laboratory
nalyses such as platelet aggregation in response to AA may
how the actual prevalence of aspirin resistance in study
opulations. This hypothesis is strongly supported by a very
ecent study of Schwartz et al. (17), in which the prevalence
f the aspirin resistance was studied in 190 patients with a
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November 1, 2005:1705–9 Aspirin Resistanceistory of myocardial infarction using AA-stimulated light
ransmittance aggregometry. These investigators found that
nly one patient was resistant to aspirin therapy. Therefore,
he application of specific methods directly indicating
OX-1 activity in platelets is recommended to indicate the
fficacy of aspirin therapy (7,8).
tudy limitations. This study is not powered to show the
elationship of aspirin resistance and demographic variables.
owever, the study population included both patients
dmitted to the hospital for PCI and patients who had
uffered SAT despite dual antiplatelet therapy. We did not
easure thromboxane metabolite levels or expression of
ctivation-dependent surface molecules, which may have
urther strengthened our conclusion that platelet aspirin
esistance is rare.
onclusions. The result of the present study indicates that
spirin resistance may be overestimated by previous reports
sing nonspecific laboratory measurements that do not
solate aspirin’s primary target, platelet COX-1. In the
urrent study, the target of aspirin therapy was assessed by
echniques using whole blood and PRP, and aspirin resis-
ance was nearly absent. Measurements of platelet response
o aspirin using more specific methods targeting COX-1
nzyme activity and also a standardized definition of aspirin
esistance are warranted to ultimately link aspirin-
ependent tests to clinical outcomes in patients with coro-
ary artery disease.
eprint requests and correspondence: Dr. Paul A. Gurbel,
inai Center for Thrombosis Research, Hoffberger Building,
uite 56, 2401 West Belvedere Avenue, Baltimore, Maryland
1215. E-mail: pgurbel@lifebridgehealth.org.
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